<DOC>
	<DOC>NCT00479622</DOC>
	<brief_summary>The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.</brief_summary>
	<brief_title>Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Glomerulonephritis, Membranous</mesh_term>
	<criteria>Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit. Diagnosis of systemic lupus erythematosus more than 6 months before study day 1. History of positive antinuclear antibody titer of &gt;1:160 or equivalent. Biopsyproven class V lupus nephritis within the last 2 years. Have been on a stable dose of oral corticosteroids (&lt;20 mg/day prednisone or equivalent) for 2 months before study day 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Membranous Nephropathy</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>